Compare American States Water Company (AWR) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American States Water Company vs Bristol-Myers Squibb Co — how do they compare? American States Water Company trades at $84.74 (market cap $3.33B), while Bristol-Myers Squibb Co trades at $58 (market cap $116.30B). The key difference: Bristol-Myers Squibb Co is far larger — about 34.9× American States Water Company's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| AWR | BMY | |
|---|---|---|
Market Cap | $3.33B | $116.30B |
Sector | Utilities | Health |
52-Week High | $85.05 | $62.37 |
52-Week Low | $70.10 | $42.60 |
Enterprise Value | $4.24B | $152.24B |
Dividend Yield | 2.37% | 4.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American States Water (AWR) trades at $85.05, up 0.64% today, with a bullish technical signal from moving averages and strong profitability metrics including a 19.66% net income margin. Recent news highlights its inclusion in TIME's America's Best Companies 2026 list and a completed $200 million ATM equity offering. The stock shows consistent dividend performance with a 71-year growth streak, though recent quarters saw mixed earnings results versus expectations.
Outlook remains stable with revenue growth to $679 million in 2026 and solid cash flow, but risks include regulatory pressures and interest rate sensitivity. Analysts are cautious with only 20% buy ratings. The stock offers defensive appeal but faces execution risks in a high-valuation environment.
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American States Water Company
American States Water provides water and electric services to over one million people in the U.S. It also manages water and wastewater systems for various military bases under long-term privatization contracts.
Read more on AWR →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
